HAIFA, Israel – December 21, 2021 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapeutics for mental disorders, announced today that the Red Herring judging panel has included GMH in its Top 100 Europe award list, which recognizes Europe’s leading private companies and celebrates these startups’ innovations and technologies across their respective industries.
“We are honored to be chosen as one of the 2021 Red Herring Top 100 Europe winners,” said Oded Kraft, GrayMatters Health Co-Founder and CEO. “Red Herring highlights promising startups and innovations, and our inclusion in its prestigious list further demonstrates the potential impact of Prism in bridging the gaps of mental disorder treatment and improving clinical outcomes.”
To help patients regain agency over their emotion regulation, GMH offers Prism, a non-invasive adjunctive therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. The company is the first to use machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers that are utilized in its proprietary treatment of mental disorders, training patients to employ self neuro-modulation techniques using an interactive audio-visual software.
“In 2021, selecting the top achievers was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “In fact, we had the toughest time in years because so many entrepreneurs had crossed significant milestones so early in the European tech ecosystem. But after much thought, rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe GrayMatters Health embodies the vision, drive and innovation that define a successful entrepreneurial venture. GrayMatters Health should be proud of its accomplishment, as the competition was very strong.”
GMH’s first product offering, Prism for PTSD, is undergoing clinical investigation in five sites across the United States and Israel, to demonstrate its efficacy and safety as an adjunct to standard Post Traumatic Stress Disorder (PTSD) treatments. Using its novel technology that fuses Electroencephalogram (EEG) and fMRI (functional Magnetic Resonance Imaging) data, Prism for PTSD produces a continuous, real-time, and accessible amygdala-EFP biomarker. During treatment sessions, an audio-visual interface responds as patients use self-neuromodulation techniques to downregulate their amygdala-EFP biomarker. GMH has plans to evaluate the clinical efficacy and safety of Prism for additional mental disorders.
About GrayMatters Health
GrayMatters Health (GMH) develops digital self-neuromodulation therapeutics for mental disorders to help patients regain agency over their emotion regulation. GMH offers Prism, a non-invasive adjunctive therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. The company’s first product candidate, Prism for PTSD, is undergoing clinical investigation in five sites across the United States and Israel, for demonstrating its efficacy and safety as an adjunct to standard PTSD treatments. Learn more by visiting our website https://graymatters.health/ and following us on LinkedIn and Twitter.
GrayMatters Health Contact
Oded Kraft, CEO